CytoDyn Inc. (CYDY) Form 8-K — Oct 19, 2026
$CYDYForm 8-KItems 5.02, 7.01, 9.01Filed Oct 19, 2026, 4:50 PM ET0001175680-26-000038Original filing
CytoDyn's board appointed CFO Robert E. Hoffman as CEO effective October 20, 2026, replacing Dr. Jacob Lalezari, who led the company since November 2023 and will stay on as Head of Research and Translational Sciences. Hoffman's base salary rises to $525,000 with a 50% bonus target and a 2.5 million-share option grant.
Key figures
- Option term end
- 2036-10-16
- Ccr5 positive rate
- 96/96 (100%)
- Option grant shares
- 2500000
- Clover target enrollment
- 65
- Hoffman bonus target pct
- 50
- M CRC market potential 2030
- >$25B globally
- Recent financing 1q26 musd
- 17.5
- Recent financing 3q26 musd
- 16.2
- Hoffman new base salary usd
- 525000
- Patients remaining on study
- 22 of 65 (34%)
- Week2 ctdna median decrease
- 86%
- Week8 shrinkage or stable disease
- 38/51 (74.5%)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.